[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"apoe-4-positive\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:apoe-4-positive":30},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,3,0,[8,50,83],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":16,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":26,"conditions":27,"keywords":31,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":38,"lastUpdatePostDateStruct":39,"startDateStruct":42,"completionDateStruct":44,"leadSponsor":46,"locationsCount":49},"100648853","phase-1-effects-of-sirolimus-on-asymptomatic-apoe4-carriers-100648853",false,"NCT07728175","Effects of Sirolimus on Asymptomatic ApoE4 Carriers","Effects of Sirolimus on Middle Aged Asymptomatic ApoE4 Carriers","Inclusion Criteria:\n\n1. Willing and able to provide informed consent\n2. Sex assigned at birth: female\n3. 45-65 years old\n4. Able to perform self-care and activities of daily living with no or minimal assistance\n5. Post-menopausal status or use of highly effective contraception. Post-menopausal is defined as either\n\n   * 12 months of spontaneous amenorrhea with an appropriate clinical profile (e.g., age-appropriate, history of vasomotor symptoms)\n   * surgical bilateral oophorectomy (with or without hysterectomy), total hysterectomy, or tubal ligation at least 6 weeks prior to screening. For oophorectomy alone, post-menopausal status must be confirmed by follow-up hormone level assessment\n   * Highly effective contraception includes intrauterine devices (IUD), oral contraceptives, or other hormonal contraceptives including injectables, transdermal patches, implants or vaginal rings, or refraining from heterosexual intercourse during the 4 weeks of taking the study drug and for 2 weeks after no longer taking the study drug\n6. Body weight of ≥ 40 kg\n7. Ability to effectively communicate with the investigator and comply with study requirements\n\nExclusion Criteria:\n\n1. Diagnosis of mild cognitive impairment (MCI), dementia, or Alzheimer's disease\n2. BMI ≥ 35 (based on MRI feasibility)\n3. Type 1 diabetes or poorly controlled type 2 diabetes (HbA1c ≥ 6.5%)\n4. History of skin ulcers or poor wound healing\n5. Current tobacco or illicit drug use or alcohol abuse (defined as ≥ 3 per day or ≥ 7 per week for women) (Per NIAAA guidelines)\n6. Use of anti-platelet or anti-coagulant medications other than aspirin\n7. Required use of medications that affect cytochrome P450 3A4 (CYP3A4) or alter cerebral blood flow (see Appendix 1 for tables of excluded medications)\n8. Immunosuppressant therapy within the last year\n9. Chemotherapy or radiation treatment within the last year\n10. Current or chronic history of liver or kidney disease or known hepatic or biliary abnormalities\n11. Untreated hypertriglyceridemia (fasting triglycerides \\\u003C 300 mg\u002Fdl)\n12. Current or chronic significant history of pulmonary disease\n13. Chronic heart failure\n14. Pregnancy or lactation\n15. Recent history (past six months) of myocardial infarction, active coronary artery disease, intestinal disorders, stroke, or transient ischemic attack\n16. Poorly controlled blood pressure (systolic BP \\> 160 or diastolic BP \\> 100 mmHg)\n17. Active inflammatory, COVID-19, autoimmune, infectious, hepatic, gastrointestinal, malignant, and\u002For severe mental illness\n18. History of, or MRI, or CT positive for, any space occupying brain lesion, including mass effect or abnormal intracranial pressure\n19. Organ transplant recipients\n20. History of Stroke\n21. History of ruptured intracranial aneurysm\n22. History of malignancy within the past 2 years, with the following exceptions:\n\n    * Localized basal cell or squamous cell carcinoma of the skin\n    * Prostate cancer confined to the gland (AJCC stage T2N0M0 or better)\n    * Cervical carcinoma in situ\n    * Breast cancer localized to the breast\n23. History of epilepsy",true,"FEMALE","45 Years","65 Years",{"count":21,"type":22},225,"ESTIMATED","INTERVENTIONAL",[25],"PHASE1","Alzheimer's disease is a devastating neurodegenerative disease characterized by accumulation of clumps (also called plaques) and bundles of fibers (also called tangles) in the brain, for which there is currently no cure.\n\nSirolimus (Rapamycin) is an FDA-approved medication which may improve the blood flow to the brain. The purpose of the clinical trial is to find out whether sirolimus can help improve blood flow and energy use in the brain in women ages 45 to 65 who have the ApoE4 gene, a gene which increases the risk of developing Alzheimer's disease later in life.\n\nThere will be two arms in this trail, a sirolimus arm and a placebo arm. A placebo is a pill that looks like the study drug, but it does not have any real medicine in it. Participants will be randomized to one arm or the other, but not to both arms. Three study visits over a 12-week period are required.\n\nParticipants will: (i) Complete some questionnaires about how well you think; (ii) Complete genetic testing for the ApoE4 gene; (iii) Have blood work, blood pressure and height and weight collected; (iv) Take either Sirolimus or a placebo daily, by mouth, for approximately 4 weeks; (v) Keep a diary of when the sirolimus or placebo is taken; (vi) Complete 2 Magnetic Resonance Imaging (MRI) exams",[28,29,30],"Genetic Predisposition to Disease","Healthy Volunteer","APOE-4 Positive",[32,33,34,35,36],"ApoE4 positive","Cerebral Blood Flow","Sirolimus","Rapamycin","Magnetic Resonance Imaging","NOT_YET_RECRUITING","2026-07-28",{"date":40,"type":41},"2026-07-30","ACTUAL",{"date":43,"type":22},"2026-12-01",{"date":45,"type":22},"2028-07-07",{"name":47,"class":48},"University of Missouri-Columbia","OTHER",1,{"id":51,"slug":52,"hasResults":11,"nctId":53,"briefTitle":54,"officialTitle":55,"acronym":4,"eligibilityCriteria":56,"healthyVolunteers":16,"sex":57,"minAge":58,"maxAge":4,"enrollmentInfo":59,"targetDuration":4,"studyType":61,"phases":4,"briefSummary":62,"conditions":63,"keywords":67,"overallStatus":73,"whyStopped":4,"lastUpdateSubmitDate":74,"lastUpdatePostDateStruct":75,"startDateStruct":77,"completionDateStruct":79,"leadSponsor":81,"locationsCount":49},"100632625","predicting-pre-dementia-100632625","NCT07516119","Predicting Pre-dementia","Assessing Tools That Predict and Stage Mild Cognitive Impairment","Inclusion Criteria:\n\nAge\n\nAge 55 years or older at enrollment.\n\nAPOE Genotype\n\nDocumented carrier of at least one APOE ε4 allele, based on prior testing (e.g., clinical APOE testing, prior genetic panel, research cohort genotyping, or direct-to-consumer testing).\n\nExisting Genomic Data for PRS\n\nWhole-genome sequencing (WGS) data already completed, with willingness to provide existing WGS data files (e.g., VCF, FASTQ, or equivalent) to the study team for Alzheimer's disease polygenic risk score (PRS) calculation; or\n\nIf WGS is not available, prior high-density or targeted genotyping array data covering Alzheimer's disease risk loci, with willingness to provide these data for PRS calculation (feasibility of array-based PRS will be evaluated case-by-case).\n\nNote: The study does not perform APOE genotyping or WGS as part of the research; these must be completed before enrollment.\n\nCognitive Status at Baseline\n\nCognitively normal or very mildly impaired at baseline, defined by:\n\nDigital cognitive assessment and\u002For Punto Test consistent with a Global Clinical Dementia Rating (CDR) of 0 or 0.5.\n\nNo clinical diagnosis of dementia.\n\nFor cognitively normal (CN) and subjective cognitive decline (SCD) participants, staging by the Progression and Risk (P\\&R) model (combining PRS, biomarker, and cognitive data) will be applied for risk stratification.\n\nAbsence of Baseline AD-MCI by Biomarkers\n\nDoes not currently qualify for Alzheimer's disease-related MCI (AD-MCI), operationalized as no evidence of MCI with plasma or CSF pTau217 level above a validated cutoff for AD-MCI pathology.\n\nCapacity and Participation Ability\n\nAble to provide informed consent (with capacity assessments and, where applicable, involvement of a legally authorized representative per institutional policy and IRB approval).\n\nAble and willing to comply with study procedures, including clinic visits, cognitive testing, and biospecimen collection.\n\nWillingness to Use Digital Monitoring Tools\n\nWilling to wear and\u002For carry digital devices for continuous or frequent monitoring (e.g., smartphone app, wearable sensors such as Oura Ring, sleep device), and to participate in app-based cognitive and speech assessments.\n\nData-Sharing Authorizations\n\nWillingness to sign data release authorizations allowing the study to obtain existing genomic data (WGS or array) and relevant electronic medical record (EMR) data needed for risk modeling and outcome adjudication.\n\nExclusion Criteria:\n\nBaseline Dementia Diagnosis\n\nClinical diagnosis of dementia of any cause at baseline.\n\nMajor Neurological Disorders Affecting Cognition\n\nHistory of major neurological conditions that in the investigator's judgment may confound cognitive assessment or outcomes, such as:\n\nParkinson's disease.\n\nStroke with residual neurological deficits.\n\nEpilepsy with frequent seizures.\n\nMajor Psychiatric Illness\n\nMajor psychiatric disorders that significantly interfere with participation or data interpretability, such as uncontrolled major depressive disorder or schizophrenia, as judged by the investigator.\n\nSerious or Unstable Medical Conditions\n\nUncontrolled systemic medical illness expected to limit life expectancy to less than approximately 3 years, including but not limited to unstable cardiac, hepatic, or renal disease.\n\nRecent Investigational or Disease-Modifying AD Treatments\n\nUse of investigational drugs or disease-modifying Alzheimer's therapies within 6 months prior to baseline, if such treatments are likely to confound biomarker trajectories or cognitive outcomes.\n\nInability or Unwillingness to Use Required Digital Tools\n\nLack of Required Genomic Documentation or Refusal to Share Data\n\nNo prior APOE genotype documenting at least one ε4 allele; or\n\nNo available WGS or suitable genotyping array data; or\n\nRefusal to share existing APOE\u002Fgenomic data and necessary EMR data with the study team.\n\nBaseline MCI with Positive pTau217\n\nVulnerable Populations Not Targeted\n\nChildren, prisoners, and pregnant individuals are not specifically targeted and will be excluded from enrollment.","ALL","55 Years",{"count":60,"type":22},100,"OBSERVATIONAL","The goal of this observational study is to learn how well a multimodal \"Progression and Risk\" (PR) model can predict and stage early mild cognitive impairment (MCI) due to Alzheimer's disease in cognitively normal or very mildly impaired ApoE4-positive adults aged 55 and older. The main questions it aims to answer are:\n\nCan a prespecified proteogenomic PR model accurately predict conversion from cognitively normal (CN) or very mildly impaired status to pTau217-positive MCI Stage I within 24 months in ApoE4-positive adults?\n\nDoes adding digital monitoring features (e.g., sleep, activity, speech), EMR-lifestyle risk scores, and plasma biomarkers to a polygenic risk score (PRS) meaningfully improve risk stratification and time-to-conversion prediction compared with simpler models (e.g., PRS alone or standard clinical risk factors)?\n\nIf there is a comparison group: Researchers will compare performance of the full multimodal PR model (integrating PRS, plasma proteomics and other omics, digital monitoring, and EMR-lifestyle data) with simpler or reduced models (for example, PRS-only, biomarker-only, or models without continuous digital monitoring) to see if the full model provides higher discrimination (AUC\u002FROC), better calibration, and improved time-to-conversion prediction for CN to pTau217-positive MCI transitions.\n\nParticipants will:\n\nProvide prior genomic data (ApoE genotype and whole-genome sequencing or high-density genotyping array data) for calculation of an ancestry- and sex-normalized Alzheimer's disease PRS and assignment to PRS-based risk strata.\n\nAttend an in-person baseline visit and follow-up visits at months 6, 12, 18, and 24 (±2 months) for clinical evaluation, neurocognitive testing (including CDR and digital cognitive batteries), and venous or capillary blood collection for plasma pTau217 and other AD biomarkers, proteomic and methylome panels, and routine safety labs when indicated.\n\nUse digital devices (e.g., Oura Ring and smartphone-based tools) for continuous or frequent remote monitoring of sleep, activity, heart rate metrics, mobility\u002Flocation, and speech-linked digital cognitive tasks, with adherence checks at study visits.\n\nUndergo optional or sub-cohort procedures as clinically indicated or as resources allow, such as EEG, retinal hyperspectral imaging, MRI, or amyloid PET, and optionally allow clinically indicated lumbar puncture CSF samples and external clinical data to be shared with the study for exploratory biomarker analyses.",[64,65,66,30],"Mild Cognitive Impairment (MCI)","Alzheimer Dementia (AD)","Alzheimer Disease (AD)",[68,69,70,71,72],"Observational cohort preclinical Alzheimer's disease","ApoE4-positive cognitively normal adults 55+","Plasma pTau217 and blood biomarkers for MCI","Polygenic risk score and proteogenomic risk model","Digital cognitive assessment and Oura Ring monitoring","RECRUITING","2026-03-31",{"date":76,"type":41},"2026-04-07",{"date":78,"type":22},"2026-04-15",{"date":80,"type":22},"2029-04-15",{"name":82,"class":48},"Prevention Research Consortium Corp.",{"id":84,"slug":85,"hasResults":11,"nctId":86,"briefTitle":87,"officialTitle":88,"acronym":4,"eligibilityCriteria":89,"healthyVolunteers":16,"sex":57,"minAge":90,"maxAge":4,"enrollmentInfo":91,"targetDuration":4,"studyType":61,"phases":4,"briefSummary":93,"conditions":94,"keywords":109,"overallStatus":73,"whyStopped":4,"lastUpdateSubmitDate":121,"lastUpdatePostDateStruct":122,"startDateStruct":124,"completionDateStruct":126,"leadSponsor":128,"locationsCount":49},"100303705","retinal-imaging-in-neurodegenerative-disease-100303705","NCT03233646","Retinal Imaging in Neurodegenerative Disease","Evaluating the Retinal and Choroidal Microvasculature and Structure Using Multimodal Retinal and Choroidal Imaging in Neurodegenerative Disease: iMIND Research Study","Inclusion Criteria:\n\n* Adults with neurodegenerative disease ((MCI, PD, AD, FTD, DLB, ALS, MS, HD, TBI, concussion, PTSD and other neurodegenerations as well as Down Syndrome)\n* Adults without neurodegenerative disease\n\nExclusion Criteria:\n\n* Inability to cooperate with or complete testing or other neurologic or age- related ocular conditions that would impact image acquisition.\n* Eyes that have had intraocular surgery, other than cataract surgery.\n\nIf two eyes satisfy the inclusion criteria, both eyes will be included in the study. If one eye satisfies the inclusion criteria, the eye that qualifies will be included in the study.","18 Years",{"count":92,"type":22},2000,"This study aims to develop and evaluate biomarkers using non-invasive optical coherence tomography (OCT) and OCT angiography (OCTA) as well as ultra-widefield (UWF) fundus photography to assess the structure and function of the retinal and choroidal microvasculature and structure in persons with mild cognitive impairment (MCI) and Alzheimer's Disease (AD), Parkinson's Disease (PD), or other neurodegenerative disease, diseases as outlined.",[95,96,97,98,99,100,101,102,30,103,104,105,106,107,108],"Alzheimer's Disease","Mild Cognitive Impairment","Parkinson's Disease","Multiple Sclerosis","Huntington Disease","Lewy Body Dementia","Frontotemporal Dementia","Amyotrophic Lateral Sclerosis (ALS)","Traumatic Brain Injury","Concussion","Post-Traumatic Stress Disorder","Down Syndrome","Neuro-Degenerative Disease","Normal Cognition",[110,111,112,113,114,115,116,117,118,119,120],"OCT angiography (OCTA)","Optical Coherence Tomography (OCT)","Vessel Density","Superficial Capillary Plexus","Retinal microvasculature","Scanning Laser Ophthalmoscopy","Ultra-widefield (UWF) Imaging","Perfusion Density","Retinal Nerve Fiber Layer","Ganglion Cell Inner Plexiform Layer","Choroidal Vascularity Index","2026-02-02",{"date":123,"type":41},"2026-02-04",{"date":125,"type":41},"2017-07-20",{"date":127,"type":22},"2026-12-31",{"name":129,"class":48},"Duke University"]